Measurements of tumor volume (Fig. 6A, B) and weight (Fig. 6C) showed that the drugs reduced GBM cell growth in vivo, and that combined treatment with CPX and BTZ significantly repressed GBM cell growth in vivo compared to treatment with CPX or BTZ alone. Here, CASC3 is linked to glioblastoma.